MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements

SAN DIEGO, April 13, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that it received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (the "Staff") notifying the...